Category Archives: Psychedelics

A judicial review request was submitted to the federal court by more than 100 doctors, psychologists, clinical counselors, social workers and nurses across Canadachallengingthe countrys health ministers decision to reject the professionals' application to use restricted psychoactive drugs for training in psilocybin-assisted therapy.

The treatment in question includes ingesting consciousness-altering substances like magic mushrooms (psilocybin) in a clinical setting, accompanied bytraditionalpsychotherapy.

The federal government had hinted earlier this year that it would refuse the applications, said Nicholas Pope, thelawyer representing the advocacy group that operates the training program andhealthcare practitioners, reported the CBC.

According to Pope, the only reason cited then was that the professionals could access an existing clinical trial. In June, with the applications official refusal, Ottawa suggested they could run their own trial. The group repliedthatexisting trials are costly and don't work for many of the professionals petitioning because of timing and location.

"Many patients on waiting lists have suicidal ideation because of their depression and many of them have end-of-life distress, have terminal cancer and could die soon," saidPope, adding that the situation would not work for a variety of reasons.

A major one is that existing trials are costly, and they don't work for many of the professionals he's representing because of timing and location.

"You can't just throw together the clinical trial in a few days," Pope said.

"Many patients on waiting lists have suicidal ideation because of their depression and many of them have end-of-life distress, have terminal cancer and could die soon."

Pope said some professionals also don't want to participate in existing trials because they are meant for research of psilocybin.

"That can interfere with training because the primary goal of a clinical trial is not the training, it's gathering information. And there's no uncertainty in the expert community about safety of psilocybin in healthy adults."

In 2020, Health Canada began granting exemptions under the Controlled Drugs and Substances Act to provide psychedelics treatment to patients suffering from end-of-life psychological distress, treatment-resistant depression and major depressive disorder.

The number of documents annually presented to court shows hundreds of Canadians asking about the therapy, yet according to Pope,there are notenough professionals in the country to provide it.

One of the patients waiting for the treatments approval said: "If I were to do too much or have a bad trip, sometimes there's no coming back from that. If I'm going to do it, I want to regulate it and I want it monitored just for safety's sake."

The case is also fighting for the governments acknowledgment of patients' rights to life, liberty and security. In reply, Health Canadas media relations officer said they are deeply concerned about the burden of mental illness on Canadians and aware that psilocybin is being studied worldwide for its potential to treat several conditions including anxiety, depression, PTSD and substance use disorders.

Health Canada's media relations officer,Marie-Pier Burelle further clarified: "Each request for an exemption... is reviewed on a case-by-case basis, taking into account all relevant considerations, including evidence of potential benefits and risks or harms to Canadians."

Photo by sebastiaan stam on Unsplash

More:

Canada: 100+ Healthcare Professionals Protest Psilocybin Access Ban For Psychedelics-Assisted Therapy Training - Benzinga

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Interest in psychedelics has grown significantly as mainstream acceptance grows andresearch uncovers more of the benefitsthat these substances possess, including how they can be used to manage a range of mental health disorders. These positive advancements have even led some states to decriminalize these controlled substances, with other states set to legalize the substances in the near future.

Lets look at some of the states that

Read More>>

NOTE TO INVESTORS:The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the companys newsroom athttps://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) createsPsychedelicNewsBreaksdesigned to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text Groovy to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visithttps://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW?Ask our Editor

PsychedelicNewsWire (PNW)San Francisco, Californiawww.PsychedelicNewsWire.com415.949.5050 Office[emailprotected]

PsychedelicNewsWire is part of theInvestorBrandNetwork.

More here:

States That Have Made Advancements Toward Legalizing Psychedelics - StreetInsider.com

Partnership is a unique opportunity to showcase Canada as a clinical and cultivation mecca

VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (Optimi or the Company), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, is pleased to announce that it has finalized a supply agreement with Bloom Psychedelic Therapy And Research Centre (Bloom), a Calgary-based provider of mental health services, including psychedelic-assisted therapies employing ketamine treatments.

Our Supply Agreement with Bloom solidifies another key relationship for Optimi, said CEO Bill Ciprick. Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimis strategic goals.

Optimi will supply Bloom with sufficient biomass of natural psilocybin to begin conducting its previously announced clinical trial in partnership with the IMPACT Clinical Trial Accelerator Program housed within Albertas Life Sciences Innovation Hub at the University of Calgary.

The proposed phase I dosing study will aim to find the optimal microdose or low dose of psilocybin that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects.

Bloom Founder and CEO, Jim Parker, says the partnership between Bloom and Optimi provides an incredible opportunity to measure true GMP-produced, Canadian-sourced natural psilocybin.

Regulatory bodies in Canada and across the world are watching Canadas fledgling psychedelics industry and how it performs in quality, safety, and efficacy, said Parker. So, I see this as an early watershed moment where good therapeutic practices, combined with Optimis Canadian-GMP-grade natural psilocybin, could establish Canada as a real leader amongst those wanting to learn from us.

Since the completion of its combined 20,000 square feet of psilocybin cultivation and production facilities in Princeton, British Columbia, Optimi has pursued a revenue-focused strategy of clinical therapeutic and research partnerships with the intention of developing logistical channels that will underpin the future of the psychedelics industry.

To echo Jims perspective on Canada defining itself as a leader in psychedelics, I believe the more Optimi produces, tests, and supplies trials and patients across the country, the more well be able to establish the benchmarks needed to develop a true cultivation mecca in Canada and eventually the world, added Ciprick.

Authorized parties interested in purchasing Optimi psilocybin and functional mushroom products, MDMA, or other synthetic psychedelics are invited to contact sales@optimihealth.ca where a member of the sales team will respond within 24 hours.

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is a homegrown, Canadian success story aiming to be the number one trusted, compassionate supplier of safe, natural, EU-GMP psilocybin and functional mushrooms across the world. Built with the purpose of producing scalable, natural mushroom formulations for transformational human experiences, the Companys 20,000 sq ft of state-of-the-art, technologically advanced in-house production and research facilities cultivate, test, and synthesize high quality mushroom strains and psychedelic substances such as MDMA.

Based in Princeton, British Columbia, Optimi is developing a robust and innovative IP portfolio through its Health Canada psilocybin Dealers License.

Optimis vision is to unlock the regenerative power of mushrooms, promote psychedelic science, and set the highest standard of trusted, GMP operational excellence in the world.

Optimis promise is to make possible a future whereby natural psychedelic alternatives aid a wide variety of mental health conditions.

ABOUT BLOOM PSYCHEDELIC THERAPY AND RESEARCH CENTRE

The Bloom Psychedelic Therapy and Research Centre is a world-class research centre committed to furthering the science supporting the use of psychedelics for depression, suicidal ideation, anxiety, PTSD, and chronic pain. We are pleased to house the University of Calgarys first research chair committed to this endeavor. The Parker Psychedelic Research Chair led out of the Mathison Centre for Mental Health Research & Education at the Hotchkiss Brain Institute in the Cumming School of Medicine, is furthering important research into alternative therapies for mental health.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations Michael Kydd Email: investors@optimihealth.caPhone: +1 (902) 880 6121 http://www.optimihealth.ca

FORWARDLOOKING STATEMENTS

This news release contains forwardlooking statements and forwardlooking information within the meaning of Canadian securities legislation (collectively, forwardlooking statements) that relate to Optimis current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as will likely result, are expected to, expects, will continue, is anticipated, anticipates, believes, estimated, intends, plans, forecast, projection, strategy, objective, and outlook) are not historical facts and may be forwardlooking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forwardlooking statements. No assurance can be given that these expectations will prove to be correct and such forwardlooking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward looking statements pertaining to activities proposed to be conducted under the Companys dealers license and associated business related to Psilocybin and Psilocin and Optimis plans, focus and objectives.

Forwardlooking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimis control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forwardlooking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID19 pandemic and other factors set forth under ForwardLooking Statements and Risk Factors in the Companys Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimis profile at http://www.sedar.com. Optimi undertakes no obligation to update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forwardlooking statement.

Any forwardlooking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

See the rest here:

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre - Marketscreener.com

Being in love is fun. But once the infatuation stage fades, those of us who want a long term relationship have to ascertain whether its actually a possibility. Realizing that youre not compatible with someone deep into a situationship is pretty shitty, and it can be very easy to ignore our intuition when the sex is great or the fun is all that matters. It can take months, or even years, to be really honest about our feelings and break free from relationships that arent serving us anymore.

This happened to me once, and it led to a psychedelics-assisted moment of clarity. I had been dating someone for months when I decided to go on a solo mushroom trip in my bedroom, because we were all in quarantine and I was feeling depressed. That trip changed the course of that relationship.

It all started with a water stain on my ceiling that began to dance, then rearranged itself into the form of a man who kind of resembled my partner. The walls began to close in on me. I spoke to the stain, which was really myself, and broke down. At some point during the three-hour trip, I realized I was very lonely in my relationship with a person who couldnt make me happy and that probably wasnt going to change. I broke up with him shortly after, and my mood improved almost overnight. That shroom-induced realization took me out of a months-long slump, giving me immense clarity and the courage to take charge of my romantic life.

Had I not sought solace in the shrooms, I know for a fact it would have taken me longer to realize I was in an unhappy relationship. And its not just me. It turns out Im one of many people who find relationship lucidity after taking recreational drugs. So what is it about psychedelics that seem to help so many of us clear up our murky relationship waters? I spoke with an expert to find out.

But first, a bit of background. Here, Ill use the term psychedelics as a stand-in for hallucinogens, which are drugs that affect neural circuits in the prefrontal cortex, or the part of the brain that regulates mood. There are many types of psychedelics, but the most common in recreational drugs tend to be LSD, DMT, and Psilocybin, the latter of which is found in shrooms and likely catalyzed my own revelation. Although research in this field is still relatively new, there are some signs that psychedelics can actually improve quality of life, especially for people with mood disorders like depression or PTSD. Bad trips can definitely happen especially if you take too much of a drug, the drug is laced, you dont hydrate, or youre in a negative environment but theres also a lot of exciting research out there about the potential health benefits of psychedelics.

But can those personal benefits change the way we relate to each other in intimate relationships? Less is known about this particular topic, but a 2016 Canadian study on the link between domestic violence and psychedelics, published in the Journal of Psychopharmacology offers some insight. Researchers at the University of British Columbia examined whether former inmates who took psychedelics were less likely to be violent toward their romantic partners than those who abstained. They found that 42% of inmates who did not take psychedelic drugs were arrested within six years for domestic battery after their release, compared to just 27% of those who had taken drugs such as LSD, psilocybin, and MDMA. One of the researchers, Peter Hendricks, had an interesting theory for why that was: One explanation is that [psychedelics] can transform people's lives by providing profoundly meaningful spiritual experiences that highlight what matters most," he said in a news release about the study.

This answer resonated with my own experience of taking shrooms and making big relationship decisions; maybe the drugs helped me prioritize my own happiness in a way I didnt know how to do in my everyday life. Buoyed by this take, I decided to interview Zachary Walsh, one of the studys authors and the co-director for the University of British Columbias Okanagan Centre for the Advancement of Psychological Science and Law, to find out if I was on the right path.

Walsh says his research suggests that psychedelics are great at helping us regulate our emotions by allowing us to notice feelings wed usually gloss over and channel them in a way thats consistent with our values. Its why he thinks inmates who previously struggled to regulate their emotional reactions were newly able to avoid engaging in intimate partner violence after they took psychedelics. In other words, theres a good chance that psychedelics help give us more clarity on situations before we act on them. I think [those realizations] may be about having a different relationship to your thoughts, Walsh says.

I initially thought my shroom trip gave me more insight on the person I was dating, but its more likely that the psychedelics just gave me more clarity on my own feelings. I was able to observe myself and my situation from a totally different vantage point, one that allowed me to access much more empathy toward myself and others. Before shrooms, I didnt know how to articulate my feelings: I was afraid of hurting my partner, and it felt inconvenient to break up when so much of our lives were intertwined. (Plus, I loved his apartment.) But the drugs helped me realize that no amount of comfort was ultimately worth that unhappiness and that the kindest thing I could do for my partner was to break up with him, rather than prolong a relationship I now knew was destined for failure.

Just as I was feeling really solid in this assessment, though, Walsh threw me a minor curveball, recapping an unpublished study hes currently working on that looked at couples who took psychedelics together. He says the preliminary results, which have not yet been peer-reviewed, suggest that couples actually grew closer and reported higher levels of willingness to compromise because, as Walsh explains, psychedelics might have helped give them insight into each others feelings. Meanwhile, the study participants who took psychedelics alone or didnt take psychedelics at all didnt seem to have tangible changes in their relationships, although its difficult to give a definitive reason why. I know there's a bit of a concern about the study, because it could be that people who are comfortable enough with each other to take psychedelics together already have a certain type of relationship, right? Walsh says. Its a chicken or egg question, but I think it's somewhat interesting when you compare it to other drugs, particularly alcohol, which is associated with worse relationship outcomes.

Perhaps I should have taken shrooms with my ex one last time before we broke up to really see if things were salvageable. Ill never know if it would have changed the outcome but regardless of what might have been, Im grateful for that trip I did take, because it helped me realize that things feel much scarier when they live inside our heads. It also taught me to trust my gut feeling about situations, whether or not Im high. Pursuing happiness, no matter how uncomfortable it can get, is a worthwhile endeavor and thats a lesson Ill carry with me in future relationships.

Stories that Fuel Conversations

Originally posted here:

Psychedelics gave me the courage to take charge of my romantic life - Mic

Its 4 am. My roommate and I are tripping on LSD, still awake after trying three times to fall asleep. We toss and turn, and each time we come out of our rooms we are in sync. We wander into the hallway, stare at one another, and laugh. We are making pancakes, leaning in with our ears perched just above the frying pan listening to the sizzle. My roommate realizes how silly we look, Hopefully our roommates dont come out and see this, he says. They wouldnt understand. And all I can say is, I just want to come down. Maybe we should have tried magic mushrooms instead.

Many have started their psychedelic journey by dropping a tab of acid, very often adding cannabis to the trip. Acid is great, Ive personally laid tabs on numerous newcomers tongues. While LSD and marijuana have their place in the psychedelic scene, they are not as popular as they once were. In recent years there has been a noticeable trend away from cannabis and LSD towards our fungi friends. With recent decriminalization in places such as Denver, DC, and Seattle, psychedelic mushrooms have become easier to obtain. And with broad mainstream exposure through advocates like Michael Pollan, mushroom use is becoming de-stigmatized. For all of these reasons, magic mushrooms are quickly becoming the mainstream psychedelic of choice.

For many people the ingestion of THC causes feelings of elation, but for others it can cause anxiety and paranoia, my partner and myself included. In high doses THC can create psychedelic experiences, but many people also experience anxiety at this dose level. It is also possible to build up a tolerance to THC, so over time even the biggest bong hits might not get you high. But THC reacts with the endocannabinoid system in our brains, whereas classical psychedelics react with the serotonin receptors. So if marijuana doesnt agree with you, or if youve found yourself developing a tolerance, then maybe a classical psychedelic is worth a try.

LSD, often labeled as the most potent psychedelic of all, was discovered by chemist Albert Hofmann in the late 1930s. A friend and fellow psychonaut named Lorenzo has described his experiences as the most intense and some of the most meaningful in his psychedelic journey. His first foray in psychedelics was with the blotter, and Lorenzo initially enjoyed acid. The electric feeling drew him in, and he stayed for the beauty, music, and revelations. But ultimately that electric feeling lingering for twelve hours was too much, and the initial joyful energy turned into comedown blues. Hes had five experiences with acid and isnt sure when or if he will try it again. For many like him, the length of the trip and intensity can be a turn off. Now, instead of LSD, he enjoys a quiet mushroom trip about three times a year.

Another problem with LSD is that it is impossible to tell what substance might be on that blotter paper. Mitchell, another seasoned psychonaut, says he no longer partakes of LSD because of inconsistencies in batches. When handed a tab (or candy, or dropper bottle) he could never tell what substance he was taking or what the dose was. It can be difficult to know if what you are obtaining is LSD or an adjacent research chemical, and there can be huge discrepancies in dosage on blotters. A small amount of LSD goes a long way, and a little too much can make the difference between a good trip and a bad trip. When buying LSD it is always wise to go through a trusted source, but ultimately you can never be sure if what youre taking is pure.

Like many people these days, Lorenzo and Mitchell have made the switch from LSD to mushrooms. With mushrooms, they feel like they know what they are getting and can dose more accurately. While every fungi will contain different levels of psilocybin, there are steps one can take to ensure an accurate dose, such as grinding and encapsulating or making a tea. With LSD there is always the potential to take too much, even on a single tab of blotter paper. However, with mushrooms, you can dose lightly at first and then eat more to adjust the dose as you go. According to Lorenzo and Mitchell, LSD seems like an all or nothing scenario.

But not everyone agrees with this trend. Perry, who can frequently be found at bluegrass music festivals, has been an avid psychonaut for the past ten years. He is a recreational tab dropper who enjoys LSD for that same electric feeling and doesnt mind how long it lasts. For him, the duration is a benefit. He can enjoy live music for hours on end, take an all day hike, or just spend a relaxing day off exploring his mind. Though Perry remains loyal to LSD, he has also noticed the recent trend towards mushrooms.

Thanks to decriminalization efforts across the country, the general publics view on psilocybin mushrooms has been trending upwards. Closest to home for myself, Washington DC decriminalized psilocybin mushrooms with a whopping 76% percent of people voting in favor of the measure. This movement has caused a ripple effect with a resurgence of interest and greater availability of magic mushrooms within DC and the surrounding areas. And this mainstreaming effect has been showing up all over the country as more cities and states vote to become decriminalized mushroom zones. With new magic mushroom ballot measures popping up in different states every month, this trend is only going to continue.

Choosing which psychedelic is right for you can be difficult, but many people are making the switch to mushrooms. LSD can be hard to find, it can be a challenge to know exactly what you are taking, and many people just dont have the time to commit twelve hours to a psychedelic trip. In contrast, the general public seems to view mushrooms as a safer and gentler option for people who are curious to try it or are just starting out. This shift in public opinion combined with the effect of decriminalization movements has led to a great resurgence of interest in fungi. So while you may prefer one psychedelic over the other, there is no denying that magic mushrooms are rapidly becoming the preferred trip of the day.

Excerpt from:

Goodbye Weed and Acid, Hello Magic Mushrooms - Psychedelic Spotlight

Career brain researchers launch innovative drug development company to advance psychedelic therapies

INTRODUCING TESSELLATE

LAS VEGAS, July 7, 2022 /PRNewswire/ -- Meet Dr. Rochelle and Dr. Dustin Hines, the husband and wife team trailblazing the future of mental health therapeutics from their lab located at The University of Nevada Las Vegas (UNLV). Both armed with PhD's (University of British Columbia) and extensive post- doctoral training (Tufts University School of Medicine) in neuroscience, Dustin and Rochelle have worked at the interface of academia and industry over their combined 40 plus year careers.

Dustin and Rochelle operate 'The Hines Group Laboratory' at UNLV, a state of the art, fully staffed, pre-clinical research facility, and one of the most advanced and accredited psychedelic research facilities in the world. Rochelle holds a license from the U.S. Drug Enforcement Agency, allowing for the handling of controlled substances for accredited research purposes. With the broad goal of advancing novel therapeutics, Dustin and Rochelle have worked on several industry sponsored research projects, and recently launched 'Tessellate', a next wave pharmaceutical company, to further the development and commercialization of novel therapeutics for an array of mental health conditions. Tessellate is working to advance the clinical applicability of psychedelics through rigorous, evidence-based discovery, with the goal of improving the efficacy and personalization of psychedelic therapies, while also mitigating the possible risks stemming from these therapeutics.

6 LIBRARIES IN DEVOLOPMENT INCLUDING 4 SETS OF MODULATORS

Tessellate has developed and rigorously tested multiple lead synthetic psychedelic molecules in the novel chemical space of substituted phenethylamines (PEA). Tessellate's PEA libraries consist of a total of 30 candidates in pre-clinical development for the treatment of major depressive disorder and PTSD. Dustin Hines commented that 'PEA psychedelics, which bear structural similarity to mescaline, are less explored in the psychedelic space and offer several possible advantages including increased specificity for the common target of psychedelics, known as the 5HT2A receptor.'

MODULATION A KEY TO EFFICACY

Tessellate's most valuable I.P. may involve it's unprecedented discoveries and insights into understanding the psychedelic experience, known as the "trip". Based on a deep understanding of the architecture of brain activity that underlies the trip, Tessellate has developed a sequence of four distinct classes of trip modulators, which can be taken during psychedelic administration, as well as before and after a therapeutic session, to 'modulate' both the patient experience as well as the therapeutic outcome. Paul Rosen, President of Tessellate, commented 'we perceive this as game changing technology and essential for the development of the entire psychedelic industry. Modulators address several concerns and anxieties that eligible patients may have regarding these disruptive therapeutic modalities. With one modulator a patient can access an offramp during a trip should they wish to stop. With another modulator a patient can remove the need to stop their current SSRI therapy before initiating psychedelic treatment. With a modulator taken pre trip the patient may enhance the efficacy of their trip, and with a modulator taken post trip the patient may solidify the psychoplastogen effects that psychedelics cause in the days following a trip, which Tessellates research has corroborated are when the long- term therapeutic benefits of psychedelics are most likely to occur'.

Tessellate is currently preparing to initiate Phase One clinical trials on its two current lead candidates, the novel PEA Tsl8 108 and the modulator Tsl8 303, while also continuing to advance preclinical validation of both its novel modulator libraries and additional PEA leads.

For inquires please contact:

Tessellate Therapeutics[emailprotected]416-728-1295

SOURCE Tessellate

Follow this link:

Meet the Married Couple Trailblazing the Development of Psychedelic Therapies - PR Newswire

A few years ago, Rabbi Zac Kamenetz of Berkeley was a novice to psychedelic substances. But after a life-changing experience as a subject in a Johns Hopkins study of psychedelic experiences in clergy, hes now a leading voice in a growing movement to normalize the use of psychedelic substances such as psilocybin (aka magic mushrooms) in the practice of Jewish spirituality.

In 2019, he told J., Someday, I see a space, maybe in the East Bay, where people can have safe and supported psychedelic experiences individually, and then integrate those experiences in a community that is invested in the application of mystical experiences with other people. This is total science fiction because it doesnt exist.

It does now. Or at least, it will for a few days later this month. Kamenetz is seeking applicants to participate in a trial run of what such a space would look like the first Jewish psychedelic cannabis Shabbaton, to take place July 22-24 at Urban Adamah, the Jewish farm in Berkeley.

The Shabbaton is a program of Shefa, the organization Kamenetz founded in the early days of the pandemic to advocate for the use of psychedelics to heal personal and intergenerational trauma in the Jewish people.

Cannabis isnt usually thought of in the same category of psychedelics as LSD or psilocybin, but it does have the benefit of being legal in California.

There are questions of what is a psychedelic, Kamenetz told J. In this instance its a shorthand for not only the substance but the setting.

In psychedelic parlance, the setting refers to the physical and social environment in which an experience takes place.

The event will begin Friday night with Shabbat candle lighting and a breath work ceremony to ease people in, Kamenetz said. Working with breath can be psychedelic itself, mood and mind altering.

The participants up to 25 of them will then spend the rest of Shabbat together on Saturday. After Shabbat ends on Saturday evening, they will begin a cannabis ceremony that will last five to six hours. Its BYO weed, but Kamenetz and his collaborators who include experienced facilitators from the Center for Medicinal Mindfulness are offering suggestions of strains available from your local dispensary.

Were being thoughtful about this. Its not like just smoking a joint on your couch and watching TV, Kamenetz said. And afterward, on Sunday, people will start talking in groups about what they encountered and experienced. Were hoping that the Jewishness of the setting and the programming will have some impact or shift on peoples desire to make their psychedelic experience or life more Jewishly rich.

Read more here:

Berkeley's psychedelic rebbe is ready for the first Jewish cannabis retreat - The Jewish News of Northern California

CaaMTech will help carry on Dr. Alexander Shulgin's legacy by developing ASRI's novel compounds

Press Release - Jul 6, 2022 10:00 PDT

LAFAYETTE, Calif., July 6, 2022 (Newswire.com) - CaaMTech, Inc. and theAlexander Shulgin Research Institute, Inc. (ASRI) jointly announced an agreement today to carry out structural and chemical analyses of previously unreported compounds designed and synthesized by the late Dr. Alexander Shulgin.

ASRI is a psychedelics discovery, development, and educational organization dedicated to continuing and extending the work of Dr. Alexander "Sasha" Shulgin.Known as "the Godfather of psychedelics," Dr. Shulgin was a biochemist and pharmacologist known for his documented synthesis - and personal testing - of hundreds of novel psychoactive compounds. Alongside his wife Ann, Dr. Shulgin published "PiHKAL: A Chemical Love Story" in 1991 and "TiHKAL: The Continuation" in 1997 (Phenethylamines andTryptamines I Have Known and Loved, respectively) documenting his synthesis and testing of novel psychedelics. Dr. Shulgin's groundbreaking research into novel psychoactive compounds was foundational to psychedelic chemistry and the CaamTech-ASRI research collaboration is a continuation of that legacy.

Several hundred compounds, collectively known as theShulgin Vault, were created by Dr. Shulgin at his famed laboratory in Lafayette, California. Many of these compounds have not yet been characterized and some may have therapeutic value, although their effects remain unknown. As a first step, compounds will be transferred to CaaMTech to be crystallized and analyzed using X-ray crystallography to determine their crystal structures.

"We are excited to discover what surprises Dr. Shulgin has left behind for us," said Dr. Nicholas Cozzi, President and Co-Founder of ASRI. "We anticipate that some of these compounds will eventually be evaluated in humans for possible therapeutic benefits, while others may be useful as tools to deepen our understanding of neuropharmacology, brain function, and consciousness itself."

Dr. Shulgin was able to design, synthesize, and test hundreds of compounds in his lab in Lafayette, California, but he did not have the benefit of modern equipment, such as X-ray diffractometers. Since that time, X-ray crystallography has become the gold standard of chemical characterization. Compounds supplied by ASRI to CaaMTech under the agreement will be transferred to the Manke Lab at UMass Dartmouth where they will be purified to yield single crystals.The compounds will then undergo X-ray powder diffraction analysis to determine their crystal structures so that future research can be conducted with rigorously pure, well-characterized molecules.

"It is an honor for us to carry on Dr. Alexander Shulgin's legacy," said Dr. Andrew Chadeayne, CEO of CaaMTech. "The current state of this industry is possible only because we're standing on the shoulders of giants such as Alexander Shulgin."

About CaaMTechCaaMTech is the foremost drug discovery and lead optimization company focused on engineering psychedelic drugs that meet the standards of modern medicine. CaaMTech is improving the health and happiness of humankind by creating and optimizing psychedelic compounds and formulations through rigorous science and continuous innovation.

About ASRIASRI is a world center for conducting scientific research into the chemistry and pharmacology of psychedelic drugs. Research activities involvede novochemical synthesis, natural product isolation, and basic chemical and pharmacological testing of newly discovered substances.

Media ContactDavis Wuolle, CaaMTechdavis@caam.tech+1.510.747.9001

Source: CaaMTech, Inc.

Read more from the original source:

CaaMTech Collaborates With the Alexander Shulgin Research Institute to Study Shulgin Compounds - Newswire

Vancouver, B.C., July 07, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE:ORIG) (the Company or Origin Therapeutics), an actively managed, psychedelics industry-focused investment issuer, is pleased to announce that it has added Clairvoyant Therapeutics (Clairvoyant) to its portfolio.

Clairvoyant is a Canadian biotech company developing psychedelic drug therapy with a focus on treatments for addiction and the clinical validation of psilocybin in the E.U., the U.K., and Canada. It is proceeding with a Health Canada-approved Phase 2 clinical trial for the clinical validation of psilocybin for the treatment of alcohol use disorder (AUD). This randomized, controlled, clinical trial will evaluate the safety and efficacy of a 25mg synthetic psilocybin capsule versus placebo, delivered in conjunction with Motivational Enhancement Therapy (MET).

Fifteen clinical trial sites are planned for Clairvoyants Phase 2 clinical trial. The first site in Canada was initiated in June. Regulatory submissions have also been submitted in the E.U. for Clairvoyant to initiate clinical trial sites.

Psychedelic medicine delivered in conjunction with therapy has been demonstrated by compelling clinical research to have potentially profound positive effects on those suffering from substance use disorders, said Alexander Somjen, CEO of Origin Therapeutics. Clairvoyant has a unique speed-to-market strategy for psilocybin therapy and an experienced drug development team. We believe that Clairvoyant makes an excellent addition to our portfolio.

According to the World Health Organization, 283 million1 people aged 15 years and older live with AUD, accounting for 5.1% of the global adult population. Alcohol dependence, the most severe form of AUD, affects 2.6% of the worlds adults, or 144 million people. The economic, healthcare, and social costs associated with alcohol in Canada alone in 2014 were estimated at $14.6B.2 Alcohol use disorder is a serious medical condition for which novel therapies are urgently needed.

We are in the midst of a substance abuse crisis, and psychedelic therapies have the potential to provide patients with a new therapeutic intervention rather than having those patients be limited to options that often do not work or that may have unpleasant side effects, said Damian Kettlewell, CEO of Clairvoyant. We are pleased to be working with the Origin Therapeutics team to drive our vision forward.

-##-

About Clairvoyant Therapeutics

Clairvoyant Therapeutics is a Canadian biotechnology company changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the E.U., the U.K., and Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026. The companys exceptional team, with a proven clinical track record and deep drug development experience, has made Clairvoyant the most advanced company globally developing psilocybin therapy for the treatment of AUD. Clairvoyant is committed to meeting the highest standards of verified social and environmental performance, public transparency and legal accountability to balance profit and purpose and is a pending B Corporation Certification. Clairvoyant is a member of Life Science BC and Biotechnology Innovation Organization (BIO).

Learn more at http://www.clairvoyantrx.com and follow the Company on LinkedIn and Twitter.

About Origin Therapeutics

Origin Therapeutics Holdings Inc (CSE:ORIG) (the Company or Origin Therapeutics) is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector.

Learn more at http://www.originpsychedelics.com and follow the Company on LinkedIn, Twitter, and Instagram

For Further Information:

Alexander SomjenChief Executive Officer and DirectorOrigin Therapeutics Holdings Inc

http://www.originpsychedelics.cominfo@originpsychedelics.com

For media inquiries, please contact: Brittany@Exvera.com

Cautionary Note

All information contained in this news release with respect to Clairvoyant was supplied by Clairvoyant for inclusion herein, and Origin Therapeutics directors and officers have relied on Clairvoyant for such information.

Forward-Looking Information and Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as may, should, could, intend, estimate, plan, anticipate, expect, believe or continue, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the Offering, the intended use of proceeds of the Offering, the filing of the Prospectus and the obtaining of receipts for the Prospectus. There are numerous risks and uncertainties that could cause actual results and the Companys plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the Companys business in general; (iii) that the proceeds of the Offering may need to be used for purposes other than as set out in this news release and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward- looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by applicable law, the Company does not intend to update these forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

1 World Health Organization. Global alcohol action plan 2022-2030 to strengthen implementation of the Global Strategy to Reduce the Harmful Use of Alcohol. First Draft. June 2021 2 BC Centre for Substance Abuse. Provincial Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder December 2019

More here:

Origin Therapeutics adds Clairvoyant Therapeutics to its Portfolio - GlobeNewswire

Psychedelic-Assisted Therapy & Medicine - Psychedelics.com

We are hard at work developing a new brand suitable to deliver the best content from psychedelics experts around the world.

We believe in a future in which humanity has found ethical, sustainable and safe ways to tap into the potential for healing and growth that psychedelic medicine offers.

Our mission is to be a consumer-friendly access point to psychedelics. If youre an industry professional, researcher, content creator, investor or have an interest in what were doing, wed love to talk.

We're seeking experts in the study of DMT, Ketamine, LSD, MDMA, Phenethylamines, Psilocybin, as well as mental and behavioral health conditions with evidenced or potential treatment efficacy through psychedelic-assisted therapy.

Calls to numbers on a specific treatment center listing will be routed to that treatment center. Additional calls will also be forwarded and returned by a quality treatment center within the USA.

Calls to any general helpline (non-facility specific 1-8XX numbers) for your visit will be answered by a licensed drug and alcohol rehab facility, a paid advertiser on Psychedelics.com.

All calls are private and confidential.

Go here to read the rest:

Psychedelic-Assisted Therapy & Medicine - Psychedelics.com